

Related Party disclosure for the half year ended September 30, 2021

a) Parent entity

Glenmark Pharmaceuticals Ltd., India

b) Entities under common control (Fellow subsidiary companies)

Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K.
Glenmark Pharmaceuticals Europe Ltd., U.K.
Glenmark Pharmaceuticals S.R.O., Czech Republic
Glenmark Pharmaceuticals SK, s.r.o., Slovak Republic
Ichnos Sciences S.A., Switzerland
Glenmark Holding S. A., Switzerland
Glenmark Pharmaceuticals SP z.o.o., Poland
Glenmark Pharmaceuticals Inc., USA
Glenmark Therapeutics Inc., USA
Glenmark Farmaceutica Ltda., Brazil
Glenmark Generics SA., Argentina
Glenmark Pharmaceuticals Mexico, S.A. DE C.V., Mexico
Glenmark Pharmaceuticals Peru SAC., Peru
Glenmark Pharmaceuticals Colombia SAS, Colombia
Glenmark Uruguay S.A., Uruguay
Glenmark Pharmaceuticals Venezuela., C.A , Venezuela
Glenmark Dominicana, SRL, Dominican Republic
Glenmark Pharmaceuticals Egypt S.A.E., Egypt
Glenmark Pharmaceuticals FZE., United Arab Emirates
Glenmark Impex L.L.C., Russia
Glenmark Philippines Inc., Philippines
Glenmark Pharmaceuticals (Nigeria) Ltd., Nigeria
Glenmark Pharmaceuticals Malaysia Sdn Bhd., Malaysia
Glenmark Pharmaceuticals (Australia) Pty Ltd., Australia
Glenmark South Africa (Pty) Ltd., South Africa
Glenmark Pharmaceuticals South Africa (Pty) Ltd., South Africa
Glenmark Pharmaceuticals B.V., Netherlands
Glenmark Arzneimittel GmbH., Germany
Glenmark Pharmaceuticals Canada Inc., Canada
Glenmark Pharmaceuticals Kenya Ltd, Kenya
Viso Farmaceutica S.L.U., Spain
Glenmark Specialty S A, Switzerland
Glenmark Pharmaceuticals Distribution S.R.O, Czech Republic
Glenmark Pharmaceuticals (Thailand) Co. Ltd., Thailand
Glenmark Pharmaceuticals Nordic AB, Sweden
Glenmark Ukraine LLC, Ukraine
Glenmark-Pharmaceuticals Ecuador S.A., Ecuador
Glenmark Pharmaceuticals Singapore Pte. Ltd., Singapore
Ichnos Sciences Biotherapeutics SA, Switzerland
Ichnos Sciences Inc., USA

c) Enterprise over which key managerial personnel exercise significant influence


Glenmark Foundation

d) Related party relationships where transactions have taken place during the period

Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Ltd., India
Glenmark Pharmaceuticals Europe Ltd., U.K.
Glenmark Farmaceutica Ltda., Brazil
Viso Farmaceutica S.L.U., Spain
Glenmark Foundation
Dr. Yasir Rawjee (Managing Director & CEO)
Mr. Sumantra Mitra (Executive Director)
Mr. Bhavesh Pujara (Chief Financial Officer)
Mr. Rudolf Corriea (Company Secretary & Compliance Officer)

e) Key Management Personnel

Mr. Glenn Saldanha (Chairman & Non-executive Director)
Mr. V S Mani (Non-executive Director)
Dr. Yasir Rawjee (Managing Director & CEO)
Mr. Sumantra Mitra (Executive Director)
Mr. Bhavesh Pujara (Chief Financial Officer)
Mr. Sridhar Gorthi (Non-executive Independent Director)
Mrs. Manju Agarwal (Non-executive Independent Director)
Mr. Taruvai Laxminarayanan Easwar (Non-executive Independent Director)
Ms. Gita Nayyar (Non-executive Independent Director)
Mr. Rudolf Corriea (Company Secretary & Compliance Officer)



(Rs. Millions)

(A) Disclosure of Related Party transactions for the Half Year ended 30th September, 2021

Sr. No.	Particulars	H1 FY22	H1 FY21
1	Sale of materials & services Glenmark Pharmaceuticals Inc., USA Glenmark Pharmaceuticals Ltd., India	189.78 4,486.00	4,675.78
2	Purchase of materials & services Glenmark Pharmaceuticals Ltd., India Viso Farmaceutica S.L.U., Spain Glenmark Pharmaceuticals Europe Ltd., U.K. Glenmark Farmaceutica Ltda., Brazil	149.84 6.70 2.27 19.26	178.07
3	Purchase of Property, Plant and Equipment Glenmark Pharmaceuticals Ltd., India	1.72	1.72
4	Expenses Reimbursed Glenmark Pharmaceuticals Ltd., India Glenmark Pharmaceuticals Inc., USA	4.54 15.62	20.16
5	Expenses Recovered Glenmark Pharmaceuticals Ltd., India Glenmark Pharmaceuticals Europe Ltd., U.K.	162.22 2.54	164.76
6	Expenditure incurred for CSR activities to Glenmark Foundation	7.50	7.50
7	Key management personnel Remuneration (Refer Note 2) Mr. Yasir Rawjee (Managing Director & CEO) Mr. Bhavesh Pujara (Chief Financial Officer) Mr. Sumantra Mitra (Executive Director) Mr. Rudolf Corriea (Company Secretary & Compliance Officer) Sitting Fees paid to Non-Executive Directors	37.64 7.51 6.53 0.87	52.55 3.10
8	Interest expense on business purchase transaction Glenmark Pharmaceuticals Ltd., India	276.92	276.92
9	Payment of amount due for business purchase transaction Glenmark Pharmaceuticals Ltd., India	9,605.59	9,605.59

(B) Related party balances

Sr. No.	Particulars	As at 30th Sep' 21	As at 30th Sep' 20
1	Receivable/(Payable) from/ (to) Fellow Subsidiaries / Holding Company Glenmark Farmaceutica Ltda., Brazil Glenmark Pharmaceuticals Europe Ltd., U.K. Glenmark Pharmaceuticals Inc., USA Viso Farmaceutica S.L.U., Spain Glenmark Pharmaceuticals Ltd., India	(11.66) (1.12) 377.58 (1.52) 2,686.68	3,049.96

